{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:54:20Z","timestamp":1790848460039,"version":"4.1.0"},"reference-count":3,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>This correspondence highlights important methodological limitations in a recently published retrospective cohort evaluating acitretin in mycosis fungoides. Inclusion of patients with stage IA disease, extensive use of concurrent skin-directed therapies and comparison with historical bexarotene trial data complicate attribution of clinical outcomes to acitretin alone. These factors may lead to overestimation of efficacy and underscore the need for cautious interpretation of retrospective analyses in cutaneous T-cell lymphoma.<\/jats:p>","DOI":"10.1093\/bjd\/ljag375","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:19:11Z","timestamp":1788419951000},"source":"Crossref","is-referenced-by-count":1,"title":["Caution in interpreting retrospective comparisons of acitretin and bexarotene in mycosis fungoides"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-5710","authenticated-orcid":false,"given":"Oleg","family":"Akilov","sequence":"first","affiliation":[{"name":"Cutaneous Lymphoma Program, University of Pittsburgh , Pittsburgh, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2026100104570735600_ljag375-B1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/bjd\/ljag073","article-title":"Dose-stratified analysis of acitretin vs. bexarotene in mycosis fungoides: a retrospective cohort study","volume":"194","author":"Garfinkel","year":"2026","journal-title":"Br J Dermatol"},{"key":"2026100104570735600_ljag375-B2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for\u00a0Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026100104570735600_ljag375-B3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","article-title":"The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma","volume":"22","author":"Kim","year":"2021","journal-title":"Am J Clin Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag375\/70935092\/ljag375.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag375\/70935092\/ljag375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:57:13Z","timestamp":1790845033000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article\/doi\/10.1093\/bjd\/ljag375\/8780896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":3,"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag375","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"ljag375"}}